PicoCELA (NASDAQ:PCLA) Stock Price Up 194.2% – Here’s Why

Posted by ABMN Staff on May 23rd, 2026

PicoCELA Inc. (NASDAQ:PCLA – Get Free Report)’s share price rose 194.2% during trading on Friday . The stock traded as high as $7.40 and last traded at $6.62. Approximately 36,812,437 shares changed hands during trading, an increase of 1,522% from the average daily volume of 2,269,378 shares. The stock had previously closed at $2.25.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on PicoCELA

PicoCELA Stock Performance

The company has a current ratio of 2.13, a quick ratio of 1.57 and a debt-to-equity ratio of 0.02. The company’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $5.32.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA at the end of the most recent reporting period.

About PicoCELA

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.